Creative Biolabs rAb Blog

Menu

Skip to content
  • Therapeutic Antibody R&D
  • Recombinant Antibody R&D
  • Antibody Engineering R&D
  • News
Therapeutic Antibodies

Therapeutic Antibodies

Creative Biolabs offers a full range of therapeutic antibodies currently available for research of a wide variety of diseases.

Learn More
Hi-affi™ Recombinant Antibodies

Hi-affi™ Recombinant Antibodies

With optimized library construction and screening processes using hybridoma or phage display technology, We have developed proprietary procedures for Hi-Affi™ recombinant antibody production.

Learn More
Single-domain Antibodies

Single-domain Antibodies

SdAbs are single-domain antibodies (SdAbs) derived from the variable regions of heavy chain of Camelidae immunoglobulins, also called VHHs. Creative Biolabs provides the most complete collection of SdAb products the world has ever had.

Learn More
Antibody Engineering Service

Antibody Engineering Service

With our unique platform, Creative Biolabs provide antibody engineering service, especially glycoengineering for our clients all over the world.

Learn More

The Ineffectiveness of Cancer Immunotherapy May Be Due to the Lack of Specific Key Immune Cells in Patients

February 22, 2023Cancer ImmunotherapyCancer Immunotherapybiorab

Nowadays, immunotherapy has dramatically changed the care of cancer patients. In the case of patients with advanced melanoma, one of the most lethal cancers of human skin, the 5-year survival rate hasRead More…

Scientists Discovered the Key Molecule Triggering Cancer Metastasis

January 2, 2023Cancer Immunotherapy, NewsCancer Immunotherapybiorab

Many cancer cells never leave their original tumor tissue. Some cancer cells have evolved the ability to migrate to other tissues, but they will become dormant once they are unable to formRead More…

Transcriptional and Immunophenotypic Profiling Reveals Molecular and Immunological Features of Cancer Tumourigenesis

December 5, 2022Cancer Immunotherapy, NewsCancer Immunotherapybiorab

The paradigm of the adenoma-cancer sequence has typically focused on cancer cells in colorectal cancer (CRC) development that is already validated to entail heterologous interactions between altered cells and their surrounding microenvironment.Read More…

Astellas Claudin18.2 Antibody Phase III Clinical Trial—Primary Endpoint Reached!

November 18, 2022News, Therapeutic Antibody R&DClaudin18.2, Zolbetuximabbiorab

Astellas recently announced positive top-line results of the Phase III SPOTLIGHT clinical trial designed to evaluate the efficacy and safety of zolbetuximab in combination with mFOLFOX6—a combination regimen including oxaliplatin, calcium folinate,Read More…

An Optimal Combination Therapy with Broadly Neutralizing Antibodies Shows Promise in Stopping HIV Escape and Rebound

October 14, 2022Recombinant Antibody R&D, Therapeutic Antibody R&Dtherapeutic antibodybiorab

In a recently published study, researchers from the Max Planck Institute for Dynamics and Self-Organization in Germany, the University of Cologne, and the University of Washington found that a carefully designed mixtureRead More…

European Commission Approved Long-Acting Antibody Therapy Evusheld for the Treatment Against COVID-19

October 1, 2022Therapeutic Antibody R&Dtherapeutic antibodybiorab

AstraZeneca recently announced that the European Commission (EC) has approved its long-acting antibody therapy Evusheld (tesaglizumab in combination with cilgravizumab, formerly AZD7442) for the treatment of adults and adolescents with severe COVID-19Read More…

Creative Biolabs Attended the 13th World Bispecific Summit as An Exhibition Partner

September 23, 2022NewsBispecific Antibody, World Bispecific Summitbiorab

As multispecifics is hailed the fourth wave of drug discovery, with more clinical candidates and commercial success than ever before, the 13th World Bispecific Summit arrived at a pivotal time to deliver the holyRead More…

Pattern and Trend of Therapeutic Antibody Discovery

July 15, 2021Antibody Engineering R&D, Therapeutic Antibody R&Dantibody discovery, therapeutic antibodybiorab

Since the first therapeutic antibody Muromonab-CD3 was approved in 1986, more than 100 antibodies have been approved for marketing. Based on their properties, antibodies can be divided into four categories: mouse antibodies,Read More…

Alternatives to Cope with Lengthy Clinical Development Process for COVID-19

April 5, 2020News, Recombinant Antibody R&DClinical Development, SARS-CoV-2, therapeutic antibodybiorab

The latest update— Cases of COVID-19 in the U.S. at a Glance on April 3, 2020, which include both confirmed and presumptive positive cases of COVID-19 reported to CDC or tested atRead More…

A Brief Introduction of MERS-CoV

February 21, 2020Recombinant Antibody R&DCoronavirus, MERS-CoV, SARS-CoVbiorab

In 2012, MERS-CoV (Middle East Respiratory Syndrome Coronavirus) was found in Saudi Arabia. The early labor symptoms caused by the viruse are similar to SARS (Severe Acute Respiratory Syndrome). Therefore, MERS-CoV isRead More…

Posts navigation

  • 1
  • 2
  • 3
  • 4
  • Next »

Categories

  • Antibody Engineering R&D
  • Cancer Immunotherapy
  • News
  • Recombinant Antibody R&D
  • Therapeutic Antibody R&D

Recent Posts

  • The Ineffectiveness of Cancer Immunotherapy May Be Due to the Lack of Specific Key Immune Cells in Patients
  • Scientists Discovered the Key Molecule Triggering Cancer Metastasis
  • Transcriptional and Immunophenotypic Profiling Reveals Molecular and Immunological Features of Cancer Tumourigenesis
  • Astellas Claudin18.2 Antibody Phase III Clinical Trial—Primary Endpoint Reached!
  • An Optimal Combination Therapy with Broadly Neutralizing Antibodies Shows Promise in Stopping HIV Escape and Rebound

Archives

Contact Us

USA – UK

Copyright © Creative Biolabs rAb Blog
Powered by WordPress , Designed and Developed by templatesnext